Investors focused on the Medical space have likely heard of GW Pharmaceuticals , but is the stock performing well in comparison to the rest of its sector peers? One simple way to answer this question is to take a look at the year-to-date performance of GWPH and the rest of the Medical group's stocks.

GW Pharmaceuticals is a member of the Medical sector. This group includes 844 individual stocks and currently holds a Zacks Sector Rank of #3. The Zacks Sector Rank gauges the strength of our 16 individual sector groups by measuring the average Zacks Rank of the individual stocks within the groups.

The Zacks Rank is a proven model that highlights a variety of stocks with the right characteristics to outperform the market over the next one to three months. The system emphasizes earnings estimate revisions and favors companies with improving earnings outlooks. GWPH is currently sporting a Zacks Rank of #2 (Buy).

The Zacks Consensus Estimate for GWPH's full-year earnings has moved 37.75% higher within the past quarter. This is a sign of improving analyst sentiment and a positive earnings outlook trend.

According to our latest data, GWPH has moved about 88.54% on a year-to-date basis. In comparison, Medical companies have returned an average of 4.09%. As we can see, GW Pharmaceuticals is performing better than its sector in the calendar year.

To break things down more, GWPH belongs to the Medical - Products industry, a group that includes 77 individual companies and currently sits at #104 in the Zacks Industry Rank. On average, stocks in this group have gained 10.39% this year, meaning that GWPH is performing better in terms of year-to-date returns.

Going forward, investors interested in Medical stocks should continue to pay close attention to GWPH as it looks to continue its solid performance.